- Name: Liu Qianwen
- Title: Chief Physician
- Email: liuqw@sysucc.org.cn
- Phone:
Dr. Qianwen Liu is a Chief Physician, Attending Professor, and Master Supervisor at the Sun Yat-sen University Cancer Center (SYSUCC).He graduated from Peking University in 2009 and has since dedicated his career to thoracic oncology. Dr. Liu is highly accomplished in the diagnosis, minimally invasive surgery, and comprehensive treatment of lung cancer, esophageal cancer, and mediastinal tumors. He was honored as a Travel Grant Scholar at the 18th World Conference on Lung Cancer (WCLC) in 2017 and won first prize in the South China Region (Esophageal Group) of the Greater China Thoracoscopic Surgery Competition in 2022. He holds several prestigious academic affiliations, including memberships in the International Association for the Study of Lung Cancer (IASLC) and the Chinese Alliance for Research in Thymic Tumors (ChART), and serves as the Secretary of the Esophageal Cancer Committee of the Guangdong Anticancer Association.
M.D. in Oncology: Sun Yat-sen University Cancer Center (2012.09 – 2016.06)
Master of Surgery: Peking University People's Hospital (2006.08 – 2009.07)
Bachelor of Clinical Medicine (Japanese Class): China Medical University (2000.09 – 2006.07)
1. Leng C#, Cui Y#, Mai Z#, Chen R#, Yuan J, Wang K, Wen J*, Fu J*, Liu Q*. Analysis of prognostic factors and establishment of prognostic model for primary mediastinal germ cell tumors: a case controlled study. International Journal of Surgery. 2023;109(9):2574-2584.
2. Wang K#, Zhong J#, Su D#, Leng C, Fu J, Liu Q*. Nomograms for predicting the prognosis in multiple primary esophageal squamous cell carcinoma. Annals of Medicine. 2024;56(1):2433685.
3. Chen J#, Zhang S#, Fu X#, Wen J#, Yang H, Zhang Y, Fu J*, Liu Q*. The characteristics and prognostic significance of esophageal squamous cell carcinoma with synchronous multiple lesions: over 10-year experience. Esophagus. 2021;18(4):851-860.
4. Ye W#, Leng C#, Chen J#, Mai Z#, Liu N#, Zhang S*, Fu J*, Liu Q*. Characteristics analyses and tumor staging proposal for primary malignant melanoma of the esophagus: a retrospective study. Diseases of the esophagus. 2025;38(1).
5. Liu Q#, Tan Z#, Lin P, Long H, Zhang L, Rong T, Meng Y, Ma G*. Impact of the number of resected lymph nodes on postoperative survival of patients with node-negative oesophageal squamous cell carcinoma. European Journal of Cardio-Thoracic Surgery. 2013;44(4):631-636.
6. Liu Q#, Fu J*, Luo K, Yang H, Wang J, Hu Y, Yang H, Bella E. Identification of EGFR and KRAS mutations in Chinese patients with esophageal squamous cell carcinoma. Diseases of the Esophagus. 2011;24(5):374-380.
7. Liu Q#, Chen J#, Wen J, Yang H, Hu Y, Luo K, Tan Z, Fu J*. Comparison of right- and left-approach esophagectomy for elderly patients with operable thoracic esophageal squamous cell carcinoma: a propensity matched study. Journal of thoracic disease. 2017;9(7):1883-1890.
8. Chen R#, Liu Q#, Li Q#, Zhu Y#, Zhao L#, Liu S#, Chen B, Liu M, Hu Y, Lin T, Li J, Chen J, Lv Y, Fu J*, Xi M*, Yang H*. A phase II clinical trial of toripalimab combined with neoadjuvant chemoradiotherapy in locally advanced esophageal squamous cell carcinoma (NEOCRTEC1901). eClinicalMedicine. 2023;62:102118.
9. Xiong G#, Chen Z#, Liu Q#, Peng F#, Zhang C#, Cheng M, Ling R, Chen S, Liang Y, Chen D*, Zhou Q*. CD276 regulates the immune escape of esophageal squamous cell carcinoma through CXCL1–CXCR2 induced NETs. Journal for ImmunoTherapy of Cancer. 2024;12(5).